HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Present status of studies on the treatment of choroidal neovascularization by Anecortave acetate].

Abstract
Choroidal neovascularization (CNV) is a major cause of vision loss in various ocular fundus diseases. The purpose of traditional therapies was to treat established CNV, but they only have limited effects. Drug treatment targeting the pathogenesis of CNV has become a hot research topic recently. Anecortave acetate is an angiostatic steroid which shows distinct mechanism of action in inhibiting neovascularization, making it different from the anti-VEGF agents (Pegaptanib, Ranibizumab and Bevacizumab). As the studies on the mechanism of CNV going more deeply, effective treatment targeting the pathogenesis of CNV will bring hope for these patients.
AuthorsXia Li, Yu-sheng Wang
Journal[Zhonghua yan ke za zhi] Chinese journal of ophthalmology (Zhonghua Yan Ke Za Zhi) Vol. 44 Issue 6 Pg. 571-4 (Jun 2008) ISSN: 0412-4081 [Print] China
PMID19035252 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Pregnadienediols
  • anecortave acetate
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Choroidal Neovascularization (drug therapy)
  • Humans
  • Pregnadienediols (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: